<DOC>
	<DOCNO>NCT02494479</DOCNO>
	<brief_summary>This study design evaluate efficacy safety Prurisol use three different oral daily dose regimen administer subject active mild moderate chronic plaque psoriasis .</brief_summary>
	<brief_title>Efficacy Safety Prurisol Administered Orally Active Mild Moderate Chronic Plaque Psoriasis</brief_title>
	<detailed_description>The total duration study participation individual subject approximately 112 day ( 16 week ) consist Screening visit , follow within 21 day Randomization Treatment Period 84 day , Follow-up Period 28 day last day study drug treatment . A window ± 3 day consider acceptable conduct schedule visit follow first visit . This study require eight ( 8 ) schedule subject visit : x Visit 1 : Screening ( Up Day 21 ) x Visit 2 : Baseline ( Day 0 ) x Visit 3 : Day 14 Interim ( ± 3 day ) x Visit 4 : Day 28 Interim ( ± 3 day ) x Visit 5 : Day 42 Interim ( ± 3 day ) x Visit 6 : Day 56 Interim ( ± 3 day ) x Visit 7 : Day 84 End Treatment/Unscheduled/ET ( ± 3 day ) x Visit 8 : Day 112 Follow-up ( ± 3 day )</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male nonpregnant female adult age 18 year clinical diagnosis stable ( least 6 month ) plaque psoriasis , include scalp intertriginous area . The extent psoriasis must meet following three ( 3 ) criterion : Total Body Surface Area ( BSA ) affect plaque psoriasis 10 % 20 % inclusive Investigator 's Global Assessment ( IGA ) score severity psoriasis 2 3 ( 5 point ordinal scale ) Identification target psoriatic lesion score 3 Target Lesion Assessment scale ( 5point ordinal scale ) Scaling . ( Other psoriatic lesion may lower scaling score . ) Females reproductive potential must pregnant Female subject reproductive potential , sexually active , must agree use reliable mean contraception The subject must agree avoid prolonged exposure sun avoid use tan booths ultraviolet light source study . The subject must provide sign dated write informed consent participate clinical study . 1 . Females reproductive potential use reliable contraception . Presence nonpsoriatic uncontrolled ( Investigator 's medical opinion ) systemic disease . Unstable form psoriasis , e.g . guttate , erythrodermic , exfoliative , palmoplantar , nail , pustular . Use within 6 month biologic treatment psoriasis Use within 24 month chemotherapy radiation therapy . Use within 2 month systemic immunosuppressive therapy . Use within 1 month ( 1 ) systemic corticosteroid , ( 2 ) systemic antibiotic , ( 3 ) systemic antipsoriasis treatment ( e.g . methotrexate , corticosporin , hydroxyurea ) , ( 4 ) PUVA therapy , ( 5 ) UVB , ( 6 ) systemic antiinflammatory treatment . Use within 2 week topical antipsoriasis drug topical corticosteroid topical retinoids . Presence condition ( e.g. , history frequent consumption substantial quantity alcohol , untreated psychiatric condition ) make unlikely requirement protocol complete . History previous use Tumor Necrosis Factor ( TNF ) blocker immunomodulating drug therapy psoriasis within 6 month prior screen . History allergic reaction formulation abacavir . Previous treatment abacavircontaining product , e.g. , Ziagen® , Epzicom® , Trizivir® .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Topical Psoriasis</keyword>
	<keyword>Mild Psoriasis</keyword>
	<keyword>Moderate Psoriasis</keyword>
	<keyword>Active Psoriasis</keyword>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Skin Diseases</keyword>
</DOC>